Monthly Archives: February 2022
Correction
Leber A, Hontecillas R, Tubau-Juni N, Lichtiger S, Bassaganya-Riera J. Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis. Gastroenterology 2022;162(3S):S1… Continue reading
Posted in News
Comments Off on Correction
AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review
Proton pump inhibitors (PPIs) are among the most commonly used medications in the world. Developed for the treatment and prevention of acid-mediated upper gastrointestinal conditions, these agents are being used increasingly for indications where their… Continue reading
Posted in News
Comments Off on AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review
Circular RNA ANAPC7 inhibits tumor growth and muscle wasting via PHLPP2-AKT-TGF-β signaling axis in pancreatic cancer
Pancreatic cancer has the highest prevalence of cancer-associated cachexia among all cancers. ZIP4 promotes pancreatic cancer progression by regulating oncogenic miR-373, and perturbation of circular RNAs (circRNAs) is associated with cancer aggressive… Continue reading
Posted in News
Comments Off on Circular RNA ANAPC7 inhibits tumor growth and muscle wasting via PHLPP2-AKT-TGF-β signaling axis in pancreatic cancer
Mucosal serotonin reuptake transporter (SERT) expression in IBS is modulated by gut microbiota via mast cell–prostaglandin E2
Increased colonic serotonin (5-HT) level and decreased serotonin reuptake transporter (SERT) expression in irritable bowel syndrome (IBS) may contribute to diarrhea and visceral hypersensitivity. We investigated whether mucosal SERT is modulated by gut… Continue reading
Posted in News
Comments Off on Mucosal serotonin reuptake transporter (SERT) expression in IBS is modulated by gut microbiota via mast cell–prostaglandin E2
Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in inflammatory bowel diseases in order to maximise benefit and to reach more stringent, objective endpoints. Optimal drug concentrations in IBD vary according to tr… Continue reading
Posted in News
Comments Off on Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
Fecal signatures of Streptococcus anginosus and Streptococcus constellatus for non-invasive screening and early warning of gastric cancer
Most patients with gastric cancer (GCa) are diagnosed at an advanced stage. We aimed to investigate novel fecal signatures for clinical application in early diagnosis of GCa. Continue reading
Posted in News
Comments Off on Fecal signatures of Streptococcus anginosus and Streptococcus constellatus for non-invasive screening and early warning of gastric cancer
Fecal signatures of Streptococcus anginosus and Streptococcus constellatus for non-invasive screening and early warning of gastric cancer
Most patients with gastric cancer (GCa) are diagnosed at an advanced stage. We aimed to investigate novel fecal signatures for clinical application in early diagnosis of GCa. Continue reading
Posted in News
Comments Off on Fecal signatures of Streptococcus anginosus and Streptococcus constellatus for non-invasive screening and early warning of gastric cancer
Entering the Era of Disease Modification in Inflammatory Bowel Disease
The inflammatory bowel diseases (IBDs), which include Crohn’s disease and ulcerative colitis, are life-long and life-limiting diseases of the gastrointestinal tract, which are increasing across the world, likely to reach a prevalence of 1% within this … Continue reading
Posted in News
Comments Off on Entering the Era of Disease Modification in Inflammatory Bowel Disease
COVID-19 vaccination in liver transplant recipients in view of evidence-based policymaking
Posted in News
Comments Off on COVID-19 vaccination in liver transplant recipients in view of evidence-based policymaking
A systematic review and meta-analysis of dietary interventions modulating gut microbiota and cardiometabolic diseases – striving for new standards in microbiome studies
Cardiometabolic diseases (CMD) have shared properties and causes. Insulin resistance is a risk factor and characteristic of CMD and has been suggested to be modulated by gut microbiota (GM) derived plasma metabolites. As diet is among the most importan… Continue reading
Posted in News
Comments Off on A systematic review and meta-analysis of dietary interventions modulating gut microbiota and cardiometabolic diseases – striving for new standards in microbiome studies